Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,937
datasets available to search
ShareScore release 0.9.0
Dataset results
2,937 results for “Multiple Myeloma”
Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients
ClinicalTrials.gov study NCT00322387. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov study NCT02441686. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT03836053. IPD Sharing: YES. Countries: 5. Publications: 1.
Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
ClinicalTrials.gov study NCT02011113. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov study NCT01335685. IPD Sharing: Not stated. Countries: 5. Publications: 1.
A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.
ClinicalTrials.gov study NCT07319897. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov study NCT02874742. IPD Sharing: Not stated. Countries: 1. Publications: 11.
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT03859427. IPD Sharing: YES. Countries: 17. Publications: 1.
An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD
ClinicalTrials.gov study NCT01985126. IPD Sharing: Not stated. Countries: 3. Publications: 6.
Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy
ClinicalTrials.gov study NCT01094548. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Reconstitution of the multiple myeloma microenvironment following lymphodepletion with BCMA CAR-T therapy
Open the record for dataset details and reuse information.
TMEM97 is correlated with the clinical features and clinical prognosis, and acts as a potential marker of multiple myeloma
<p><strong>Abstract</strong></p> <p><strong>Background</strong>: TMEM97 has been proven to be involved in many biological processes of malignancies. This study was designed to investigate the role of TMEM97 in multiple myeloma progression and clinical features and prognosis. We also predicted the potential mechanism of TMEM97 in MM prognosis.</p> <p><strong>Methods:</strong> In the present study, five GEO datasets including GSE24080, GSE13591, GSE2113, GSE19784 and GSE2658 were obtained from the National Cancer for Biotechnology Information database for analysis of TMEM97 expression and clinical features and prognosis in MM.We performed GSEA analysis to investigate the potential mechanism of TMEM97 in MM.</p> <p><strong>Results: </strong>We collected multiple myeloma data based on GEO datasets, and demonstrated the expression level of TMEM97 increased with the progression of multiple myeloma. Also the expression level of TMEM97 was correlated significantly with ISS stage in MM patients.Additionally, TMEM97 was more likely to be associated with important factors of MM prognosis, such as cytogenetic, B2M, CRP, LDH, BMPC, MRI and HGB. The multivariate analysis showed that TMEM97 was an independent factor for OS and EFS. In addition, top positively correlated genes with TMEM97 covered PUS7, GGCT, PFAS, CTPS1, RFC4 and PRMT3.</p> <p><strong>Conclusion:</strong>The expression of TMEM97 was a factor affecting the survival and prognosis of MM patients. TMEM97 may be an important prognosis biomarker and promising therapeutic target in multiple myeloma.</p>
Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT02626481. IPD Sharing: Not stated. Countries: 2. Publications: 0.
CART-19 for Multiple Myeloma
ClinicalTrials.gov study NCT02135406. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Expanded Natural Killer (NK) Cells for Multiple Myeloma Study
ClinicalTrials.gov study NCT01040026. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients
ClinicalTrials.gov study NCT02384083. IPD Sharing: Not stated. Countries: 1. Publications: 20.
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov study NCT05091372. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)
ClinicalTrials.gov study NCT00858234. IPD Sharing: YES. Countries: 0. Publications: 1.
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma
ClinicalTrials.gov study NCT00113204. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Interleukin-12 in Treating Patients With Multiple Myeloma
ClinicalTrials.gov study NCT00003149. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.